AGP Picks
View all

Precision STING targeting could help turn cold tumors hot

Oct. 19, 2026
Precision STING targeting could help turn cold tumors hot
By AI, Created 12:15 UTC, Oct 19, 2026, AGP -

A new review argues that carefully timed, tumor-specific activation of the cGAS-STING pathway could improve immunotherapy by converting immune-desert cancers into inflamed tumors. The authors outline delivery platforms, biomarker strategies, and combination regimens that may reduce toxicity and expand the number of patients who respond.

Why it matters: - Immune checkpoint inhibitors have transformed cancer care, but only a subset of patients benefit. - Many tumors remain “cold” because they lack T-cell infiltration or are protected by suppressive cells and barriers. - Precision STING delivery could help convert those tumors into inflamed, treatment-responsive tumors. - A more targeted approach may improve efficacy while reducing the systemic toxicity that has limited earlier STING drugs.

What happened: - Researchers from Tianjin University of Traditional Chinese Medicine, Tianjin Medical University Cancer Institute & Hospital, and Tianjin First Central Hospital published a review in Cancer Biology & Medicine. - The review focuses on the cGAS-STING pathway as a switch between innate and adaptive immunity in cancer. - The paper says acute STING activation can support antitumor immunity, while chronic or mistimed activation can promote immunosuppression and resistance. - The article includes DOI 10.20892/j.issn.2095-3941.2026.0058.

The details: - cGAS senses cytosolic double-stranded DNA and produces 2′3′-cGAMP. - 2′3′-cGAMP activates STING on the endoplasmic reticulum. - STING then moves to the Golgi, where palmitoylation and oligomerization help recruit TBK1 and activate IRF3. - That signaling drives type I interferon production and inflammatory cytokines. - Acute activation can promote dendritic-cell maturation, antigen cross-presentation, CD8⁺ T-cell priming, and natural killer cell activity. - Chronic activation linked to chromosomal instability can sustain NF-κB signaling and support immunosuppression. - ENPP1-mediated breakdown of extracellular cGAMP can also help tumors evade immunity and spread. - The review maps STING-based strategies to tumor microenvironment states. - For immune-desert tumors, the paper points to vaccines and oncolytic viruses. - For immune-excluded tumors, the paper highlights nanotechnology, vascular normalization, and cancer-associated fibroblast reprogramming. - For myeloid-suppressed tumors, the paper points to antibody-drug conjugates, immune-stimulating antibody conjugates, and IDO inhibitors. - For exhausted-inflamed tumors, the paper suggests STING agonists combined with immune checkpoint inhibitors or adoptive cell therapy. - The review also surveys delivery platforms including antibody-drug conjugates, immune-stimulating antibody conjugates, nanoparticles, bacterial vectors, and exosomes. - The authors say first-generation STING agonists have struggled with poor pharmacokinetics, systemic toxicity, and weak intratumoral delivery.

Between the lines: - The review argues against a one-size-fits-all approach to STING activation. - The core idea is to activate STING in the right place, at the right time, and in the right cells. - That distinction matters because tumor-localized signaling can boost dendritic-cell function, while systemic activation can trigger immune-suppressing feedback. - Biomarker-driven patient selection will likely be necessary if STING therapies are to work in the clinic. - Human TMEM173 polymorphisms could affect how patients respond.

What's next: - The authors say clinical validation will be needed to determine whether these delivery and combination strategies improve outcomes. - Future trials may need to match STING platforms to specific tumor microenvironment phenotypes. - The review suggests combining STING activation with checkpoint inhibitors, cancer vaccines, adoptive cell therapy, IDO inhibitors, or oncolytic viruses. - Better safety controls, dosing schedules, and tumor-specific delivery systems will be important to limit off-target inflammation. - If the framework holds up, it could broaden the number of patients who benefit from immunotherapy.

The bottom line: - Precision STING targeting may turn a powerful immune pathway into a more practical cancer therapy by aligning the drug, the delivery system, and the tumor environment.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

China Arts & Entertainment Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

China Arts & Entertainment Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.